Remote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic Attack

Table 3

P-selectin (median fluorescence) in response to arachidonic acid (AA) and adenosine diphosphate (ADP) by antiplatelet medication taken prior to randomisation split by whether treatment was only given acutely after stroke/TIA but prior to randomisation (i.e., none before stroke) or had been taken chronically prior to stroke/TIA (whether or not also taken after stroke and before randomisation). Data are number (%) or mean (standard deviation). Comparisons by Chi-square test or one-way analysis of variance. Highlighted data reflects comparisons that are significant statistically.

	Aspirin			Asp/Clop			Asp/Dip			Clopidogrel
	Acute	Chronic		Acute	Chronic		Acute	Chronic		Acute	Chronic
AA
Number (%)	270 (61.5)	169 (38.5)		11 (84.6)	2 (15.4)		15 (50)	15 (50)		36 (54.5)	30 (45.5)
Mean (SD)	190 (155)	222 (203)	0.065	193 (91)	272 (42)	0.27	308 (307)	197 (125)	0.21	733 (398)	522 (372)	0.03
<400 (%)	260 (96.3)	156 (92.3)	0.068	10 (90.9)	2 (100)	0.66	12 (80)	14 (93.3)	0.28	9 (25)	15 (50)	0.036
<500 (%)	263 (97.4)	160 (94.7)	0.14	11 (100)	2 (100)	1.00	12 (80)	14 (93.3)	0.28	10 (27.8)	15 (50)	0.064
ADP
Number (%)	271 (60.2)	179 (39.8)		11 (84.6)	2 (15.4)		21 (50)	21 (50.0)		36 (54.5)	30 (45.5)
Mean (SD)	928 (282)	967 (328)	0.18	757 (262)	1010 (57)	0.22	1276 (350)	938 (428)	0.008	616 (267)	578 (304)	0.60
<860 (%) [33]	116 (42.8)	66 (36.9)	0.21	7 (63.6)	0 (0)	0.097	3 (14.3)	9 (42.9)	0.040	30 (83.3)	25 (83.3)	1.00
<625 (%)	35 (12.9)	26 (14.5)	0.63	4 (36.4)	0 (0)	0.31	1 (4.8)	6 (28.6)	0.038	21 (58.3)	18 (60.0)	0.89
<500 (%)	19 (7)	11 (6.1)	0.72	1 (9.1)	0 (0)	0.66	1 (4.8)	3 (14.3)	0.29	14 (38.9)	12 (40.0)	0.93

Protocol violation [34].